The authors reported that all participants significantly decreased body fat percentage, IR, TG levels, total cholesterol, ALT, and AST, pointing towards an effective improvement in markers related to NAFLD [26]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.